(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its…
(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease…
(IN BRIEF) New research from the University of East Anglia has found that being vaccinated against Covid-19 can halve the…
(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert…
(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced…
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca…
A thousand people are needed for ground-breaking research being carried out by the University of Birmingham into an incurable lung…
Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and…
LONDON, 20-Apr-2018 — /EuropaWire/ — Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints…
https://youtu.be/T-9OK8yHfmQ Philips joins COPD Foundation and family of late Leonard Nimoy in asking the world to #BreatheBoldly on social media…
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study…
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death…
OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients…
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM…
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress LONDON, 8-9-2014 — /EuropaWire/…
28-6-2013 — /europawire.eu/ — AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held…